|
[1]BATALLER R, BRENNER DA.Liver fibrosis[J].J Clin Invest, 2005, 115 (2) :209-218.
|
|
[2]PAPASTERGIOU V, TSOCHATZIS E, BURROUGHS AK.Non-invasive assessment of liver fibrosis[J].Ann Gastroenterol, 2012, 25 (3) :218-231.
|
|
[3]NEUMAN MG, COHEN LB, NANAU RM.Hyaluronic acid as a non-invasive biomarker of liver fibrosis[J].Clin Biochem, 2016, 49 (3) :302-315.
|
|
[4]CALES P, OBERTI F, MICHALAK S, et al.A novel panel of blood markers to assess the degree of liver fibrosis[J].Hepatology, 2005, 42 (6) :1373-1381.
|
|
[5]NAN YM, FU N, YU J, et al.Study of the mechanism of rosiglitazone preventing hepatic fibrosis in non-alcoholic steatohepatitis in mice[J].Chin Hepatol, 13 (6) :475-478. (in Chinese) 南月敏, 付娜, 于君, 等.罗格列酮阻止非酒精性脂肪性肝纤维化进展作用机制的研究[J].肝脏, 13 (6) :475-478.
|
|
[6]PARK HJ, KIM HG, WANG JH, et al.Comparison of TGF-β, PDGF, and CTGF in hepatic fibrosis models using DMN, CCl4, and TAA[J].Drug Chem Toxicol, 2016, 39 (1) :111-118.
|
|
[7]SZABO G, CSAK T.Inflammasomes in liver diseases[J].J Hepatol, 2012, 57 (3) :642-654.
|
|
[8]SHOJI, YOSHIO S, MANO Y, et al.Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J].Sci Rep, 2016, 6:28814.
|
|
[9]WASMUTH HE, LAMMERT F, ZALDIVAR MM, et al.Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans[J].Gastroenterology, 2009, 137 (1) :309-319.
|
|
[10]BERRES ML, TRAUTWEIN C, SCHMEDING M, et al.Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection[J].Hepatology, 2011, 53 (2) :596-603.
|
|
[11]WALD O, PAPPO O, SAFADI R, et al.Involvement of the CX-CL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus[J].Eur J Immunol, 2004, 34 (4) :1164-1174.
|
|
[12]WEI H, LI B, ZHANG R, et al.Serum GP73, a marker for evaluating progression in patients with chronic HBV infections[J].PLoSOne, 2013, 8 (2) :e53862.
|
|
[13]LE P, GAO GS, DONG FB, et al.Serum Golgi protein 73 and three noninvasive serum score systems for diagnosis of liver fibrosis in patients with chronic hepatitis B[J].Chin J Nosocomiology, 2016, 26 (11) :2529-2531. (in Chinese) 乐萍, 高国生, 董飞波, 等.血清高尔基体蛋白73及3种评分系统对慢性乙型肝炎患者肝纤维化的预测价值研究[J].中华医院感染杂志, 2016, 26 (11) :2529-2531.
|
|
[14]MUSSO G, GAMBINO R, CASSADER M, et al.Meta-analysis:natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med, 2011, 43 (8) :617-649.
|
|
[15]CUSI K, CHANG Z, HARRISON S, et al.Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2014, 60 (1) :167-174.
|
|
[16]NIELSEN MJ, KARSDAL MA, KAZANKOV K, et al.Fibrosis is not just fibrosis-basement membrane modelling and collagen metabolism differs between hepatitis B-and C-induced injury[J].Aliment Pharmacol Ther, 2016, 44 (11-12) :1242-1252.
|
|
[17]RODERFELD M, HEMMANN S, ROEB E.Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs) [J].Z Gastroenterol, 2007, 45 (1) :25-33.
|
|
[18]LICHTINGHAGEN R, HUEGEL O, SEIFERT T, et al.Expression of matrix metalloproteinase-2 and-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C[J].Clin Chem, 2000, 46 (2) :183-192.
|
|
[19]KEROLA A, LAMPELA H, LOHI J, et al.Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia[J].J Pathol Clin Res, 2016, 2 (3) :187-198.
|
|
[20]LI SL, CAO YN, ZHAO JR, et al.Increased expression of microfibrillar-associated protein 4 in chronic hepatitis B patients[J].Chin J Hepatol, 2012, 20 (6) :474-475. (in Chinese) 李森林, 曹玉宁, 赵景润, 等.微纤维相关蛋白4在慢性乙型肝炎患者肝组织中的表达及其意义[J].中华肝脏病杂志, 2012, 20 (6) :474-475.
|
|
[21]MOLLEKEN C, POSCHMANN G, BONELLA F, et al.MFAP4:a candidate biomarker for hepatic and pulmonary fibrosis?[J].Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33 (1) :41-50.
|
|
[22]SCHIAVON LL, CARVALHO-FILHO RJ, NARCISO-SCHIA-VON JL, et al.YKL-40-and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCVchronic infection[J].Scand J Gastroenterol, 2010, 45 (5) :615-622.
|
|
[23]RATH T, RODERFELD M, GULER C, et al.YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis[J].Scand JGastroenterol, 2011, 46 (11) :1369-1380.
|
|
[24]JOHANSEN JS, CHRISTOFFERSEN P, MØLLER S, et al.Serum YKL-40 is increased in patients with hepatic fibrosis[J].J Hepatol, 2000, 32 (6) :911-920.
|
|
[25]KAMADA Y, AKITA M, TAKEDA Y, et al.Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis[J].PLoS One, 2013, 8 (6) :e66328.
|
|
[26]TAWARA S, TATSUMI T, IIO S, et al.Evaluation of fucosylated haptoglobin and Mac-2 binding protein as serum biomarkers to estimate liver fibrosis in patients with chronic hepatitis C[J].PLoSOne, 2016, 11 (3) :e0151828.
|
|
[27]EL-AHWANY E, NAGY F, ZOHEIRY M, et al.Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis[J].Electron Physician, 2016, 8 (1) :1804-1810.
|
|
[28]CHEN Q, WU F, WANG M, et al.Transcriptional profiling and miR-NA-Target Network analysis identify potential biomarkers for efficacy evaluation of Fuzheng-Huayu formula-treated hepatitis B caused liver cirrhosis[J].Int J Mol Sci, 2016, 17 (6) :e883.
|
|
[29]CERMELLI S, RUGGIERI A, MARRERO JA, et al.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease[J].PLoS One, 2011, 6 (8) :e23937.
|
|
[30]RODERBURG C, URBAN GW, BETTERMANN K, et al.MicroRNA profiling reveals a role for miR-29 in human and murine liver fibrosis[J].Hepatology, 2011, 53 (1) :209-218.
|
|
[31]NINOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers[J].PLoS One, 2013, 8 (6) :e66086.
|
|
[32]ZHANG L, HUANG YL, WANG H, et al.Increased expression of lncRNA AK053349 in peripheral blood mononuclear cells from patients with primary biliary cirrhosis and its clinical significance[J].Int J Lab Med, 2013, 34 (20) :2656-2659. (in Chinese) 张蕾, 黄元兰, 王慧, 等.原发性胆汁性肝硬化患者单个核细胞中lncRNA AK053349表达增高及意义[J].国际检验医学杂志, 2013, 34 (20) :2656-2659.
|
|
[33]FU N, NIU X, WANG Y, et al.Role of LncRNA-activated by transforming growth factor beta in the progression of hepatitis C virus-related liver fibrosis[J].Discov Med, 2016, 22 (119) :29-42.
|
|
[34]HUANG H, SHIFFMAN ML, CHEUNG RC, et al.Identification o two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C[J].Gastroentrology, 2006, 130 (6) :1679-1687.
|
|
[35]XU MY, QU Y, JIA XF, et al.Serum proteomic MRM identify peptide ions of transferrin as new fibrosis markers in chronic hepatitis B[J].Biomed Pharmacother, 2013, 67 (7) :561-567.
|
|
[36]BELL LN, THEODORAKIS JL, VUPPALANCHI R, et al.Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (1) :111-120.
|
|
[37]CALLEWAERT N, van VLIERBERGHE H, van HECKE A, et al.Noninvasive diagnosis of liver cirrhosis using DNA sequencerbased total serum protein glycomics[J].Nat Med, 2004, 10 (4) :429-434.
|
|
[38]TOKUSHIGE K, HASHIMOTO E, KODAMA K, et al.Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease[J].J Gastroenterol, 2013, 48 (12) :1392-1400.
|
|
[39]EMBADE N, MARINO Z, DIERCKS T, et al.Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum 1H-NMR spectroscopy[J].PLoS One, 2016, 11 (5) :e0155094.
|
DownLoad: